Hypertension, Vol 15, 327-331, Copyright © 1990 by American Heart Association
AV Chobanian, CC Haudenschild, C Nickerson and R Drago
The effects of 9 months of orally administered captopril (25-50 mg/kg body
wt/day) on aortic atherosclerosis was examined in normotensive Watanabe
heritable hyperlipidemic rabbits. Captopril caused a significant decrease
in aortic atherosclerosis. Total aortic surface involvement by lesions was
reduced from 48 +/- 3.6% in control Watanabe rabbits to 30 +/- 3.9% with
captopril treatment (p less than 0.01). Most of the decrease could be
accounted for by a marked reduction in atherosclerosis of descending
thoracic aortas from 49 +/- 5.2% to 15 +/- 3.9% in control and
captopril-related groups, respectively (p less than 0.001). Significant
decrease in cholesterol content of descending thoracic aorta was also
observed in captopril-treated rabbits. Microscopic examination of the
arterial lesions in captopril-treated animals suggested a relative decrease
in cellularity and increase in extracellular matrix as compared with
untreated animals. These studies indicate that captopril has a potent
antiatherosclerotic action in the Watanabe heritable hyperlipidemic rabbit.
ARTICLES
Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit
Whitaker Cardiovascular Institute, Boston University School of Medicine, Massachusetts.
This article has been cited by other articles:
 |
|
 |
|
  M. Bohm, F. Mahfoud, C. Werner, K. Teo, and M. Baumhakel Cardiovascular protection: a breakthrough for high-risk patients Eur. Heart J. Suppl., December 1, 2009; 11(suppl_F): F19 - F26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Chobanian Does It Matter How Hypertension Is Controlled? N. Engl. J. Med., December 4, 2008; 359(23): 2485 - 2488. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Takahashi, E. Suzuki, R. Takeda, S. Oba, H. Nishimatsu, K. Kimura, T. Nagano, R. Nagai, and Y. Hirata Angiotensin II and tumor necrosis factor-{alpha} synergistically promote monocyte chemoattractant protein-1 expression: roles of NF-{kappa}B, p38, and reactive oxygen species Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2879 - H2888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nussberger, J.-F. Aubert, K. Bouzourene, M. Pellegrin, D. Hayoz, and L. Mazzolai Renin Inhibition by Aliskiren Prevents Atherosclerosis Progression: Comparison With Irbesartan, Atenolol, and Amlodipine Hypertension, May 1, 2008; 51(5): 1306 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Elmi, Z. Sadeghi, S. Elmi, B. Daraei, and M. Ghazi-Khansari Hepatoprotective role of captopril on paraquat induced hepatotoxicity Human and Experimental Toxicology, October 1, 2007; 26(10): 789 - 794. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Suganuma, V. R. Babaev, M. Motojima, Y. Zuo, N. Ayabe, A. B. Fogo, I. Ichikawa, M. F. Linton, S. Fazio, and V. Kon Angiotensin Inhibition Decreases Progression of Advanced Atherosclerosis and Stabilizes Established Atherosclerotic Plaques J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2311 - 2319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Wysocki, E. P. Kwiatkowska, U. Kazimierczak, W. Suchorska, D. W. Kowalczyk, and A. Mackiewicz Captopril, an Angiotensin-Converting Enzyme Inhibitor, Promotes Growth of Immunogenic Tumors in Mice. Clin. Cancer Res., July 1, 2006; 12(13): 4095 - 4102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Saijonmaa, T. Nyman, and F. Fyhrquist Regulation of angiotensin-converting enzyme production by nicotine in human endothelial cells Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2000 - H2004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nishimatsu, E. Suzuki, H. Satonaka, R. Takeda, M. Omata, T. Fujita, R. Nagai, T. Kitamura, and Y. Hirata Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1770 - H1776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sekuri, F S. Cam, E. Ercan, I. Tengiz, A. Sagcan, E. Eser, A. Berdeli, and M. Akin Renin-angiotensin system gene polymorphisms and premature coronary heart disease Journal of Renin-Angiotensin-Aldosterone System, March 1, 2005; 6(1): 38 - 42. [Abstract] [PDF]
|
|
|
|
|
|
J. S. Sim, J. B. Dick, and A. D Struthers Statin therapy increases vascular sensitivity to angiotensin II in hypercholesterolaemic patients Journal of Renin-Angiotensin-Aldosterone System, September 1, 2004; 5(3): 109 - 113. [Abstract] [PDF]
|
|
|
|
|
|
L. Mazzolai, M. A. Duchosal, M. Korber, K. Bouzourene, J. F. Aubert, H. Hao, V. Vallet, H. R. Brunner, J. Nussberger, G. Gabbiani, et al. Endogenous Angiotensin II Induces Atherosclerotic Plaque Vulnerability and Elicits a Th1 Response in ApoE-/- Mice Hypertension, September 1, 2004; 44(3): 277 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Karagiannis, K. Balaska, K. Tziomalos, T. Gerasimidis, D. Karamanos, A. Papayeoryiou, and C. Zamboulis Lack of an association between angiotensin converting enzyme gene polymorphism and peripheral arterial occlusive disease Vascular Medicine, August 1, 2004; 9(3): 189 - 192. [Abstract] [PDF]
|
|
|
|
|
|
E. Suzuki, H. Satonaka, H. Nishimatsu, S. Oba, R. Takeda, M. Omata, T. Fujita, R. Nagai, and Y. Hirata Myocyte Enhancer Factor 2 Mediates Vascular Inflammation via the p38-Dependent Pathway Circ. Res., July 9, 2004; 95(1): 42 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Saijonmaa, T. Nyman, P. Stewen, and F. Fyhrquist Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2096 - H2102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Satonaka, E. Suzuki, H. Nishimatsu, S. Oba, R. Takeda, A. Goto, M. Omata, T. Fujita, R. Nagai, and Y. Hirata Calcineurin Promotes the Expression of Monocyte Chemoattractant Protein-1 in Vascular Myocytes and Mediates Vascular Inflammation Circ. Res., March 19, 2004; 94(5): 693 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T Hirsch and D. Duprez The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease Vascular Medicine, November 1, 2003; 8(4): 273 - 278. [Abstract] [PDF]
|
|
|
|
|
|
C. Staniloae, A. J. Schwab, A. Simard, R. Gallo, I. Dyrda, G. Gosselin, J. Lesperance, J. W. Ryan, and J. Dupuis In vivo measurement of coronary circulation angiotensin-converting enzyme activity in humans Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H17 - H22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Schieffer Interaction of interleukin-6 and angiotensin II in atherosclerosis: culprit for inflammation? Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A25 - A30. [Abstract] [PDF]
|
|
|
|
|
|
E. Lonn, H.C. Gerstein, M. Smieja, J.F.E. Mann, and S. Yusuf Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A43 - A48. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Maddison Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition Rheumatology, September 1, 2002; 41(9): 965 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Brasier, A. Recinos III, and M. S. Eledrisi Vascular Inflammation and the Renin-Angiotensin System Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1257 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R Chiong and A. B Miller Review: Renin-angiotensin system antagonism and lipid-lowering therapy in cardiovascular risk management Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 96 - 102. [Abstract] [PDF]
|
|
|
|
|
|
E. Suzuki, H. Nishimatsu, H. Satonaka, K. Walsh, A. Goto, M. Omata, T. Fujita, R. Nagai, and Y. Hirata Angiotensin II Induces Myocyte Enhancer Factor 2- and Calcineurin/Nuclear Factor of Activated T Cell-Dependent Transcriptional Activation in Vascular Myocytes Circ. Res., May 17, 2002; 90(9): 1004 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D Timmis Diabetes: Relationship to ischaemic heart disease Br. Med. Bull., October 1, 2001; 59(1): 159 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Keidar, R. Heinrich, M. Kaplan, T. Hayek, and M. Aviram Angiotensin II Administration to Atherosclerotic Mice Increases Macrophage Uptake of Oxidized LDL: A Possible Role for Interleukin-6 Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1464 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Niebauer, P. S Tsao, P. S Lin, R. E Pratt, and J. P Cooke Cholesterol-induced upregulation of angiotensin II and its effects on monocyte-endothelial interaction and superoxide production Vascular Medicine, August 1, 2001; 6(3): 133 - 138. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Petrovic, M. Zorc, V. Kanic, and B. Peterlin Interaction Between Gene Polymorphisms of Renin-angiotensin System and Metabolic Risk Factors in Premature Myocardial Infarction Angiology, April 1, 2001; 52(4): 247 - 252. [Abstract] [PDF]
|
|
|
|
|
|
W. Wojakowski, J. Gminski, K. Siemianowicz, M. Goss, and M. Machalski The influence of angiotensin-converting enzyme inhibitors on the aorta elastin metabolism in diet-induced hypercholesterolaemia in rabbits Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1): 37 - 42. [Abstract] [PDF]
|
|
|
|
|
|
M.-S. Zhou, A. Adam, and L. Raij Review: Interaction among angiotensin II, nitric oxide and oxidative stress Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S59 - S63. [PDF]
|
|
|
|
 |
|
 E. M. Lonn, S. Yusuf, V. Dzavik, C. I. Doris, Q. Yi, S. Smith, A. Moore-Cox, J. Bosch, W. A. Riley, and K. K. Teo Effects of Ramipril and Vitamin E on Atherosclerosis : The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) Circulation, February 20, 2001; 103(7): 919 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Saijonmaa, T. Nyman, R. Kosonen, and F. Fyhrquist Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H885 - H891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Kintscher, S. Wakino, S. Kim, E. Fleck, W. A. Hsueh, and R. E. Law Angiotensin II Induces Migration and Pyk2/Paxillin Phosphorylation of Human Monocytes Hypertension, February 1, 2001; 37(2): 587 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Sparrow, C. A. Burton, M. Hernandez, S. Mundt, H. Hassing, S. Patel, R. Rosa, A. Hermanowski-Vosatka, P.-R. Wang, D. Zhang, et al. Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol Lowering Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 115 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kiarash, P. J. Pagano, M. Tayeh, N.-E. Rhaleb, and O. A. Carretero Upregulated Expression of Rat Heart Intercellular Adhesion Molecule-1 in Angiotensin II- but Not Phenylephrine- Induced Hypertension Hypertension, January 1, 2001; 37(1): 58 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Nickenig, A. Stablein, S. Wassmann, C. Wyen, C. Muller, and M. Bohm Acute effects of ACE inhibition on coronary endothelial dysfunction Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 361 - 364. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Batalla, R. Alvarez, J. R. Reguero, S. Hevia, G. Iglesias-Cubero, V. Alvarez, A. Cortina, P. Gonzalez, M. M. Celada, A. Medina, et al. Synergistic Effect between Apolipoprotein E and Angiotensinogen Gene Polymorphisms in the Risk for Early Myocardial Infarction Clin. Chem., December 1, 2000; 46(12): 1910 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. MacMahon, N. Sharpe, G. Gamble, A. Clague, C. Ni Mhurchu, T. Clark, H. Hart, J. Scott, H. White, and PART-2 Collaborative Research Group Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease J. Am. Coll. Cardiol., August 1, 2000; 36(2): 438 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Vaughan AT1 Receptor Blockade and Atherosclerosis : Hopeful Insights Into Vascular Protection Circulation, April 4, 2000; 101(13): 1496 - 1497. [Full Text] [PDF]
|
|
|
|
|
|
W. B. Strawn, M. C. Chappell, R. H. Dean, S. Kivlighn, and C. M. Ferrario Inhibition of Early Atherogenesis by Losartan in Monkeys With Diet-Induced Hypercholesterolemia Circulation, April 4, 2000; 101(13): 1586 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kim and H. Iwao Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases Pharmacol. Rev., March 1, 2000; 52(1): 11 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. V. de Cavanagh, F. Inserra, L. Ferder, and C. G. Fraga Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2000; 278(3): R572 - R577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hayek, J. Attias, R. Coleman, S. Brodsky, J. Smith, J. L. Breslow, and S. Keidar The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice Cardiovasc Res, December 1, 1999; 44(3): 579 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. de las Heras, P. Aragoncillo, R. Maeso, S. Vazquez-Perez, J. Navarro-Cid, M. DeGasparo, J. Mann, L. M. Ruilope, V. Cachofeiro, and V. Lahera AT1 Receptor Antagonism Reduces Endothelial Dysfunction and Intimal Thickening in Atherosclerotic Rabbits Hypertension, October 1, 1999; 34(4): 969 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Linz, P. Wohlfart, B. A Scholkens, T. Malinski, and G. Wiemer Interactions among ACE, kinins and NO Cardiovasc Res, August 15, 1999; 43(3): 549 - 561. [Full Text] [PDF]
|
|
|
|
|
|
N. J. Brown, M. Agirbasli, and D. E. Vaughan Comparative Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Antagonism on Plasma Fibrinolytic Balance in Humans Hypertension, August 1, 1999; 34(2): 285 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kranzhofer, J. Schmidt, C. A. H. Pfeiffer, S. Hagl, P. Libby, and W. Kubler Angiotensin Induces Inflammatory Activation of Human Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, July 1, 1999; 19(7): 1623 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ihara, H. Urata, A. Kinoshita, J. Suzumiya, M. Sasaguri, M. Kikuchi, M. Ideishi, and K. Arakawa Increased Chymase-Dependent Angiotensin II Formation in Human Atherosclerotic Aorta Hypertension, June 1, 1999; 33(6): 1399 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rabbani and E. J. Topol Strategies to achieve coronary arterial plaque stabilization Cardiovasc Res, February 1, 1999; 41(2): 402 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hoshida, N. Yamashita, K. Kawahara, T. Kuzuya, and M. Hori Amelioration by Quinapril of Myocardial Infarction Induced by Coronary Occlusion/Reperfusion in a Rabbit Model of Atherosclerosis : Possible Mechanisms Circulation, January 26, 1999; 99(3): 434 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Brown, M. A. Agirbasli, G. H. Williams, W. R. Litchfield, and D. E. Vaughan Effect of Activation and Inhibition of the Renin-Angiotensin System on Plasma PAI-1 Hypertension, December 1, 1998; 32(6): 965 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Makaritsis, H. Gavras, Y. Du, A. V. Chobanian, and P. Brecher {alpha}1-Adrenergic Plus Angiotensin Receptor Blockade Reduces Atherosclerosis in Apolipoprotein E–Deficient Mice Hypertension, December 1, 1998; 32(6): 1044 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Saijonmaa and F. Fyhrquist Upregulation of angiotensin converting enzyme by atrial natriuretic peptide and cyclic GMP in human endothelial cells Cardiovasc Res, October 1, 1998; 40(1): 206 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Yang, M. I. Phillips, D. Mohuczy, H. Meng, L. Shen, P. Mehta, and J. L. Mehta Increased Angiotensin II Type 1 Receptor Expression in Hypercholesterolemic Atherosclerosis in Rabbits Arterioscler Thromb Vasc Biol, September 1, 1998; 18(9): 1433 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kamide, M. T. Hori, J.-H. Zhu, J. D. Barrett, P. Eggena, and M. L. Tuck Insulin-Mediated Growth in Aortic Smooth Muscle and the Vascular Renin-Angiotensin System Hypertension, September 1, 1998; 32(3): 482 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Potter, C. G. Sobey, P. K. Tompkins, J. D. Rossen, and D. D. Heistad Evidence That Macrophages in Atherosclerotic Lesions Contain Angiotensin II Circulation, August 25, 1998; 98(8): 800 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Brown and D. E. Vaughan Angiotensin-Converting Enzyme Inhibitors Circulation, April 14, 1998; 97(14): 1411 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hasdai, P. J.M. Best, C. R. Cannan, V. Mathew, R. S. Schwartz, D. R. Holmes Jr, and A. Lerman Acute Endothelin-Receptor Inhibition Does Not Attenuate Acetylcholine-Induced Coronary Vasoconstriction in Experimental Hypercholesterolemia Arterioscler Thromb Vasc Biol, January 1, 1998; 18(1): 108 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Schwenke Comparison of Aorta and Pulmonary Artery : I. Early Cholesterol Accumulation and Relative Susceptibility to Atheromatous Lesions Circ. Res., September 19, 1997; 81(3): 338 - 345. [Abstract] [Full Text]
|
|
|
|
|
|
D. C. Schwenke Comparison of Aorta and Pulmonary Artery : II. LDL Transport and Metabolism Correlate With Susceptibility to Atherosclerosis Circ. Res., September 19, 1997; 81(3): 346 - 354. [Abstract] [Full Text]
|
|
|
|
|
|
S. J. Rials, Y. Wu, X. Xu, R. A. Filart, R. A. Marinchak, and P. R. Kowey Regression of Left Ventricular Hypertrophy With Captopril Restores Normal Ventricular Action Potential Duration, Dispersion of Refractoriness, and Vulnerability to Inducible Ventricular Fibrillation Circulation, August 19, 1997; 96(4): 1330 - 1336. [Abstract] [Full Text]
|
|
|
|
|
|
F. Diet, R. E. Pratt, G. J. Berry, N. Momose, G. H. Gibbons, and V. J. Dzau Increased Accumulation of Tissue ACE in Human Atherosclerotic Coronary Artery Disease Circulation, December 1, 1996; 94(11): 2756 - 2767. [Abstract] [Full Text]
|
|
|
|
|
|
D. deBlois, D. M. Lombardi, E. J. Su, A. W. Clowes, S. M. Schwartz, and C. M. Giachelli Angiotensin II Induction of Osteopontin Expression and DNA Replication in Rat Arteries Hypertension, December 1, 1996; 28(6): 1055 - 1063. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. V. Chobanian and R. W. Alexander Exacerbation of Atherosclerosis by Hypertension: Potential Mechanisms and Clinical Implications Arch Intern Med, September 23, 1996; 156(17): 1952 - 1956. [Abstract] [PDF]
|
|
|
|
 |
|
 A. V. Chobanian Calcium Channel Blockers: Lessons Learned From MIDAS and Other Clinical Trials JAMA, September 11, 1996; 276(10): 829 - 830. [Abstract] [PDF]
|
|
|
|
|
|
G.B. J. Mancini, G. C. Henry, C. Macaya, B. J. O'Neill, A. L. Pucillo, R. G. Carere, T. J. Wargovich, H. Mudra, T. F. Luscher, M. I. Klibaner, et al. Angiotensin-Converting Enzyme Inhibition With Quinapril Improves Endothelial Vasomotor Dysfunction in Patients With Coronary Artery Disease: The TREND (Trial on Reversing ENdothelial Dysfunction) Study Circulation, August 1, 1996; 94(3): 258 - 265. [Abstract] [Full Text]
|
|
|
|
|
|
Y.-Q. Chen, D. M. Gilliam, B. Rydzewski, and A. J. Naftilan Multiple Enhancer Elements Mediate Induction of c-fos in Vascular Smooth Muscle Cells Hypertension, June 1, 1996; 27(6): 1224 - 1233. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Furukawa, A. Matsumori, T. Hirozane, and S. Sasayama Angiotensin II Receptor Antagonist TCV-116 Reduces Graft Coronary Artery Disease and Preserves Graft Status in a Murine Model : A Comparative Study With Captopril Circulation, January 15, 1996; 93(2): 333 - 339. [Abstract] [Full Text]
|
|
|
|
|
|
S. Keidar, M. Kaplan, and M. Aviram Angiotensin II–Modified LDL Is Taken Up by Macrophages Via the Scavenger Receptor, Leading to Cellular Cholesterol Accumulation Arterioscler Thromb Vasc Biol, January 1, 1996; 16(1): 97 - 105. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Rossi, A. Rossi, A. Sacchetto, E. Pavan, and A. C. Pessina Hypertensive Cerebrovascular Disease and the Renin-Angiotensin System Stroke, September 1, 1995; 26(9): 1700 - 1706. [Abstract] [Full Text]
|
|
|
|
|
|
A. V. Chobanian, S. Hope, and P. Brecher Dissociation Between the Antiatherosclerotic Effect of Trandolapril and Suppression of Serum and Aortic Angiotensin-Converting Enzyme Activity in the Watanabe Heritable Hyperlipidemic Rabbit Hypertension, June 1, 1995; 25(6): 1306 - 1310. [Abstract] [Full Text]
|
|
|
|
|
|
T. A. Manolio, J. A. Cutler, C. D. Furberg, B. M. Psaty, P. K. Whelton, and W. B. Applegate Trends in Pharmacologic Management of Hypertension in the United States Arch Intern Med, April 24, 1995; 155(8): 829 - 837. [Abstract] [PDF]
|
|
|
|
|
|
T. Kitazono, R. C. Padgett, M. L. Armstrong, P. K. Tompkins, and D. D. Heistad Evidence That Angiotensin II Is Present in Human Monocytes Circulation, February 15, 1995; 91(4): 1129 - 1134. [Abstract] [Full Text]
|
|
|
|
|
|
B. J. Materson and R. A. Preston Angiotensin-Converting Enzyme Inhibitors in Hypertension: A Dozen Years of Experience Arch Intern Med, March 14, 1994; 154(5): 513 - 523. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Weber and J. H. Laragh Hypertension: Steps Forward and Steps Backward: The Joint National Committee Fifth Report Arch Intern Med, January 25, 1993; 153(2): 149 - 152. [Abstract] [PDF]
|
|